David Brailer’s June 11, 2026, commentary in Health Affairs Forefront describes how US health care payers and providers use ...

The administration is expected to appeal at least parts of the ruling, but the timing and scope of appeal is unclear. Meanwhile, HHS may offer flexibility on the current August 12 deadline for ...

The premise of Medicaid as a policy laboratory rests on generating knowledge through rigorous evaluation. Yet, too often, ...

Under the FDA’s regulatory authority, drug companies, prescribers, and patients operate under one national standard for drug ...

Three federal actions are putting intense pressure on the clinical dietetics workforce, just when it’s needed the most.

Recent evidence on cash transfers and child health is mixed, suggesting that cash transfers may be a necessary but ...

The Clover decision and resulting instability offer an opportunity to step back and assess how the Medicare Advantage quality ...

So far, efforts to reform society’s relationship with screen time have focused on children. Now, as it becomes increasingly ...

We’ve built global highways for approved medicines and left clinical trial access on something closer to dirt roads.

If the relevant question is how to obtain the greatest health value for the money spent, a cost-effectiveness analysis or ...

Since taking office, the Trump administration has inflicted chaos on Title X, the only federal program that supports the ...

The 340B fights of 2026 are being waged as disputes over fairness and intent. Underneath, they are disputes over data.